1599-5453 Contact Us KO
Neuromodulation

Botulinum Toxin Therapy

Botulinum Toxin Therapy

Botulinum toxin therapy utilizes the neurotoxin produced by Clostridium botulinum to block acetylcholine release at the neuromuscular junction, thereby controlling muscle overactivity, pain, and autonomic hypersecretion.

2026-03-29

At a Glance

Botulinum toxin is used as a standard treatment in neurology for chronic migraine (PREEMPT protocol), cervical dystonia, blepharospasm, and hemifacial spasm [1]. In chronic migraine, injections at 31 sites every 12 weeks have been reported to reduce monthly headache days by approximately 8-9 days [2]. It also has approved indications for hyperhidrosis and neurogenic bladder, with effects lasting approximately 3-6 months [3].

Definition and Overview

Botulinum neurotoxin (BoNT) is a neurotoxin produced by Clostridium botulinum. Of the seven serotypes (A through G), types A and B are used clinically for therapeutic purposes.

It blocks acetylcholine release by cleaving SNARE proteins essential for synaptic vesicle membrane fusion at the neuromuscular junction, producing muscle relaxation, secretion inhibition, and pain modulation. Since the FDA first approved it for blepharospasm treatment in 1989, its indications have been continuously expanded across neurology, rehabilitation medicine, and urology [1].

Mechanism of Action

Neuromuscular Blockade

Botulinum toxin type A cleaves SNAP-25 protein, while type B cleaves synaptobrevin (VAMP). When synaptic vesicles cannot fuse with the nerve terminal membrane, acetylcholine is not released, resulting in relaxation of the target muscle.

Pain Inhibition Mechanism

The efficacy in migraine cannot be explained by muscle relaxation alone. Botulinum toxin inhibits the release of pain-related neuropeptides such as CGRP and substance P from trigeminal nerve terminals and interferes with TRPV1 receptor membrane insertion, thereby blocking peripheral sensitization.

Secretion Inhibition

It blocks acetylcholine release from sympathetic cholinergic sudomotor nerves to suppress sweating. It also blocks acetylcholine release at the bladder detrusor muscle to control detrusor overactivity.

Neurological Indications

Chronic Migraine

The PREEMPT I and II studies demonstrated that onabotulinumtoxinA (Botox) showed significant efficacy over placebo in chronic migraine (headache on 15 or more days per month, with migraine on 8 or more of those days), leading to FDA approval in 2010 [2].

The procedure (PREEMPT protocol) is as follows.

  • Injection at a total of 31 sites with 155 units (maximum 195 units)
  • Injection sites: frontalis (4 sites), corrugator (2 sites), procerus (1 site), temporalis (8 sites), occipitalis (6 sites), cervical paraspinal (4 sites), trapezius (6 sites)
  • Repeated at 12-week intervals
  • Onset of effect: 2-4 weeks after the first cycle, with maximum effect after 2-3 cycles

A Cochrane systematic review confirmed an additional reduction of approximately 3.5 monthly headache days compared to placebo [5].

Cervical Dystonia (Torticollis)

Cervical dystonia is one of the most well-established indications for botulinum toxin [4]. Direct injection into the affected muscles alleviates abnormal contractions. Approximately 85-90% of patients respond, with repeat injections at 12-16 week intervals.

Blepharospasm and Hemifacial Spasm

In blepharospasm and hemifacial spasm, small doses are injected into the orbicularis oculi and adjacent facial muscles to control involuntary eye closure. Level A evidence supports its efficacy [1].

Spasticity

Injections into target muscles alleviate spasticity and promote functional recovery in post-stroke, cerebral palsy, multiple sclerosis, and spinal cord injury-related spasticity.

Autonomic-related Indications

Hyperhidrosis

Intradermal injection significantly suppresses sweating in axillary (underarm), palmar (palm), and plantar (sole) hyperhidrosis. In axillary hyperhidrosis, the effect duration is approximately 6-12 months, with sweat volume reduction of approximately 80-90% [3].

Neurogenic Bladder

Intravesical injection (onabotulinumtoxinA 200 units) for detrusor overactivity-related incontinence reduces incontinence frequency by approximately 50-70%, with effects lasting approximately 6-9 months.

Chronic Sialorrhea

For sialorrhea (excessive salivation) in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other conditions, injections into the parotid and submandibular glands regulate salivary secretion.

Side Effects

Local Side Effects

  • Injection site pain, bruising, swelling (most common)
  • Ptosis: approximately 2-4% with facial injections
  • Transient muscle weakness: toxin diffusion to muscles adjacent to the injection site

Systemic Side Effects (Rare)

  • Generalized muscle weakness from remote toxin spread
  • Dysphagia, respiratory difficulty (with high-dose cervical muscle injections)
  • Flu-like symptoms (fatigue, myalgia)

Neutralizing Antibody Formation

Neutralizing antibodies develop in approximately 3-5% of patients receiving repeat injections, potentially reducing treatment efficacy. Using the minimum effective dose and maintaining appropriate injection intervals (minimum 12 weeks) are important for minimizing antibody formation [1].

Available Formulations

  • OnabotulinumtoxinA (Botox): most widely used, with a chronic migraine indication
  • AbobotulinumtoxinA (Dysport): cervical dystonia, spasticity
  • IncobotulinumtoxinA (Xeomin): complexing protein-free formulation, lower risk of antibody formation
  • RimabotulinumtoxinB (Myobloc/NeuroBloc): type B toxin, alternative when type A antibodies develop

Potency differs between formulations, so caution is required when converting doses.

Frequently Asked Questions

It is an FDA-approved treatment for chronic migraine (headache on 15 or more days per month). The PREEMPT study demonstrated that injecting 155-195 units across 31 cranial and cervical sites every 12 weeks reduces monthly headache days by approximately 8-9 days [2]. Efficacy has not been established for episodic migraine (fewer than 15 days per month).

Very fine needles (30-32 gauge) are used, so pain is mild. A slight stinging sensation may be felt during scalp and forehead injections, and cooling spray or topical anesthetic cream can be applied if needed. The procedure takes approximately 10-15 minutes.

It varies by indication, but effects generally last approximately 3-4 months (12-16 weeks). Chronic migraine injections are repeated at 12-week intervals and cervical dystonia at 12-16 week intervals. For hyperhidrosis, effects may last up to 6-12 months [3].

Injection site pain, bruising, and transient muscle weakness are the most common side effects. Eyelid drooping (ptosis) may occur in approximately 2-4% of migraine treatment cases but is usually temporary [2]. Very rarely, dysphagia and respiratory difficulty due to systemic toxin spread have been reported.

Long-term safety data have not identified cumulative toxicity from repeated injections. However, neutralizing antibodies may form in some patients (approximately 3-5%), reducing efficacy, in which case switching to a different serotype toxin is considered [1].

References

  1. [1] Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J (2016). "Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache." Neurology, 86: 1818-1826. DOI PubMed
  2. [2] Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010). "OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program." Headache, 50: 921-936. DOI PubMed
  3. [3] Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, Truong D (2013). "Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders." Toxicon, 67: 141-152. DOI PubMed
  4. [4] Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C (2013). "Phenomenology and classification of dystonia: a consensus update." Movement Disorders, 28: 863-873. DOI PubMed
  5. [5] Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ (2018). "Botulinum toxins for the prevention of migraine in adults." Cochrane Database of Systematic Reviews, 6: CD011616. DOI PubMed

Related Articles

Migraine Treatment
Botulinum ToxinBotoxChronic Migraine TreatmentDystonia TreatmentHyperhidrosis TreatmentNeuromuscular BlockadeBotulinum Injection

This content is provided for medical information purposes only and cannot replace professional medical advice. If you have symptoms, please consult a specialist.

Are you concerned about related symptoms?

Get an accurate diagnosis at OSANG Neurosurgery.

02-514-8887 Contact Us